Literature DB >> 12406095

AC133+ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis.

Nicolas Forraz1, Ruth Pettengell, Pierre-Antoine Deglesne, Colin P McGuckin.   

Abstract

Umbilical cord blood (UCB) provides immediate access to haemopoietic stem/progenitor cells (HSPC) but low cell number restricts use in full adult bone marrow reconstitution. This study investigated early ex vivo expansion kinetics of UCB AC133+ cells (2-4 x 10(4)/ml), mononuclear cells (MNC, 1-2 x 10(6)/ml) and AC133negative cells (AC133(neg), 2-4 x 10(4)/ml) in stroma-free 8 d liquid culture (fetal bovine serum-supplemented Iscove's-modified Dulbecco's medium (IMDM) with either 'K36EG'[c-Kit ligand, interleukin 3 (IL-3), IL-6, erythropoietin, granulocyte colony-stimulating factor] or 'TPOFL' (thrombopoietin, Flt-3 ligand). Cell enumeration, apoptosis assay and AC133/CD34/CD38 antigen immunophenotyping were performed at d 0, 3, 5 and 8. All three cell populations went through a proliferation lag phase between d 3 and d 5. AC133+ cells recovered better from lag phase with significantly higher fold increase (FI) when compared with MNC and AC133(neg) populations (K36EG FI: 15.04 +/- 5.46; TPOFL FI: 8.59 +/- 2.92, P < 0.05). After 8 d, populations lacking AC133+ cells were significantly more inclined to undergo apoptosis under proliferative conditions (P < 0.01). Also, when compared with K36EG, 8 d TPOFL-expanded AC133+ cells encompassed a significantly higher percentage of AC133+ and CD34+ early HSPC (K36EG: 20.50 +/- 2.36; TPOFL: 47.00 +/- 7.69; P < 0.05). In conclusion, TPOFL synergism demonstrated the potential for AC133+ HSPC ex vivo expansion inducing self-renewal, early HSPC maintenance and promoting cell survival status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406095     DOI: 10.1046/j.1365-2141.2002.03828.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  Production of stem cells with embryonic characteristics from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz; M-O Baradez; S Navran; J Zhao; R Urban; R Tilton; L Denner
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

Review 2.  Evaluation of neural plasticity in adult stem cells.

Authors:  Jeffrey J Ross; Catherine M Verfaillie
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-12       Impact factor: 6.237

Review 3.  Potential for access to embryonic-like cells from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

4.  Oct-4A isoform is expressed in human cord blood-derived CD133 stem cells and differentiated progeny.

Authors:  M Howe; J Zhao; Y Bodenburg; C P McGuckin; N Forraz; R G Tilton; R J Urban; L Denner
Journal:  Cell Prolif       Date:  2009-03-25       Impact factor: 6.831

Review 5.  Promising new sources for pluripotent stem cells.

Authors:  Christian Leeb; Marcin Jurga; Colin McGuckin; Richard Moriggl; Lukas Kenner
Journal:  Stem Cell Rev Rep       Date:  2010-03       Impact factor: 5.739

Review 6.  The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.

Authors:  N Forraz; C P McGuckin
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

7.  A new methodological sequence to expand and transdifferentiate human umbilical cord blood derived CD133+ cells into a cardiomyocyte-like phenotype.

Authors:  Yu-Xin Cui; Wael Kafienah; M-S Suleiman; Raimondo Ascione
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 8.  The benefits and risks of stem cell technology.

Authors:  A Leventhal; G Chen; A Negro; M Boehm
Journal:  Oral Dis       Date:  2011-11-18       Impact factor: 3.511

9.  Thrombopoietin, flt3-ligand and c-kit-ligand modulate HOX gene expression in expanding cord blood CD133 cells.

Authors:  C P McGuckin; N Forraz; R Pettengell; A Thompson
Journal:  Cell Prolif       Date:  2004-08       Impact factor: 6.831

10.  Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin.

Authors:  L Denner; Y Bodenburg; J G Zhao; M Howe; J Cappo; R G Tilton; J A Copland; N Forraz; C McGuckin; R Urban
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.